Trade Names:
Synonyms:
Status: Approved (2016)
Entry Type: Antibody
Molecule Category: UNKNOWN
ATC: L04AC13
UNII: BTY153760O

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Interleukin 17A inhibitor FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Psoriasis 4 D011565 ClinicalTrials
Psoriasis 4 D011565 FDA
Severe Acute Respiratory Syndrome 3 D045169 ClinicalTrials
Spondylitis, Ankylosing 3 D013167 ClinicalTrials
Pityriasis Rubra Pilaris 2 D010916 ClinicalTrials
Arthritis, Rheumatoid 2 D001172 ClinicalTrials
Pemphigoid, Bullous 2 D010391 ClinicalTrials
Pyoderma 2 D011711 ClinicalTrials
Diabetes Mellitus, Type 1 2 D003922 ClinicalTrials

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
25.17
Injury, poisoning and procedural complications
21.53
Skin and subcutaneous tissue disorders
16.41
Immune system disorders
7.43
Gastrointestinal disorders
5.27
Infections and infestations
4.63
Respiratory, thoracic and mediastinal disorders
3.21
Musculoskeletal and connective tissue disorders
2.81
Nervous system disorders
2.66
Vascular disorders
2.5

Cross References

Resources Reference
CAS NUMBER 1143503-69-8
ChEMBL CHEMBL1743034
FDA SRS BTY153760O
Guide to Pharmacology 7541